Guest guest Posted July 25, 2010 Report Posted July 25, 2010 HCV ADVOCATE WEEKLY NEWS REVIEW Week Ending: July 24, 2010 This Issue: SciClone Announces Enrollment of First Patient In Its Phase 2 Trial of SCV-07 In Hepatitis C St. Louis VA Medical Center Problems Identified More Than a Year Ago A New Era in HCV Drug Development HCV Raises Risk of Stroke, Maybe MI, in HIV-Positive US Veterans Depression Overlooked in Patients with Hepatitis C; Compromising HCV Therapy Lower Patient Productivity and Higher Healthcare Benefit Costs Add to Burden of HCV Infection Viramune Boosts Hep C Treatment Efficacy in People with HIV Does Nevirapine Improve Hepatitis C Treatment Outcomes in HIV/HCV Co-Infected Individuals? Prevention and Treatment Can Block Worldwide Health Threat Hepatitis with Many Forms Risk Behaviors for Hepatitis B High, Vaccination Remains Low among Adults Hepatitis C and Insulin Resistance NVHR Responds to New York Times Article on Hepatitis C Testing Achillion Pharmaceuticals Announces Nomination of NS5A Inhibitor as a Lead Clinical Candidate for Treatment of HCV People with HIV/Hepatitis C Co-Infection More Likely to Develop Osteoporosis Hep C Treatment Effective in HIV Patients with Normal Liver Enzymes Hepatitis C Virus Can Remain Viable for Months in a Liquid Environment at Low Temperatures Anesthesia Misuse Could Lead to Hepatitis Virus Transmission Hepatitis C: Cure and Control Needed Now Lawmakers Debate Whether to Extend, Expand, End Syringe Sales http://www.hcvadvocate.org/news/newsRev/2010/NewsRev-371.html Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.